XML 37 R14.htm IDEA: XBRL DOCUMENT
v3.25.2

Other Financial Statement Details | 6 Months Ended
--- | ---
Jun. 28, 2025
Other Financial Statement Details [Abstract] |
Other Financial Statement Details |
Note 5 : | Other Financial Statement Details
Accounts Receivable We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $1.6 billion during the first six months of 2025 ($1.0 billion during the first six months of 2024). After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution. Inventories
(In Millions) |  | Jun 28, 2025 |  | Dec 28, 2024
Raw materials |  | $ | 1,194 |  |  | $ | 1,344 |
Work in process |  | 6,484 |  |  | 7,432 |
Finished goods |  | 3,699 |  |  | 3,422 |
Total inventories |  | $ | 11,377 |  |  | $ | 12,198 |
Property, Plant, and Equipment We invest in and deploy manufacturing assets in response to manufacturing capacity requirements based upon short- and long-term demand forecasts and economic returns relative to capital outlays. We regularly monitor, evaluate, and adjust our manufacturing capacity footprint in response to a number of volatile factors that impact our business, including demand for our products and services and the state of the semiconductor industry as a whole. In connection with the preparation of our Consolidated Condensed Financial Statements for the second quarter of 2025, we evaluated our current process technology node capacities relative to projected market demand for our products and services, concluding that our manufacturing asset portfolio exceeded manufacturing capacity requirements. Upon performing a re-use assessment, we impaired and accelerated depreciation for certain manufacturing assets. In total, we recorded non-cash impairments and accelerated depreciation charges of $460 million and $337 million, respectively, in the second quarter of 2025, net of certain items. All charges were recognized in cost of sales within our Intel Foundry operating segment. We also incurred $416 million of other non-cash asset impairment and accelerated depreciation charges as a direct result of the 2025 Restructuring Plan (see "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements). These charges were included as a component of "corporate unallocated expenses" within the restructuring and other category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements. Other Accrued Liabilities Other accrued liabilities include deferred compensation of $3.0 billion as of June 28, 2025 ($3.3 billion as of December 28, 2024). Interest and Other, Net
|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Interest income |  | $ | 210 |  |  | $ | 320 |  |  | $ | 455 |  |  | $ | 643 |
Interest expense |  | (227) |  |  | (294) |  |  | (526) |  |  | (552) |
Other, net |  | (78) |  |  | 54 |  |  | (197) |  |  | 134 |
Total interest and other, net |  | $ | (95) |  |  | $ | 80 |  |  | $ | (268) |  |  | $ | 225 |
Interest expense is net of $368 million of interest capitalized in the second quarter of 2025 and $680 million in the first six months of 2025 ($374 million in the second quarter of 2024 and $737 million in the first six months of 2024). Other, net includes a $94 million charge in the first six months of 2025 related to the sale of our NAND memory business (refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements). Government Incentives In the first six months of 2025, we recognized $890 million in grants under the CHIPS Act, of which capital-related incentives reduced gross property, plant and equipment by $742 million, and operating-related incentives benefited operating income by $148 million, substantially all of which was recorded in cost of sales. Of the $148 million operating grants recognized in the first six months of 2025, $60 million was recognized in the second quarter of 2025. Additionally, in the first six months of 2025 we recognized an advanced manufacturing investment tax credit of $759 million ($1.3 billion in the first six months of 2024), which may be refunded to us in cash to the extent it exceeds our outstanding income tax liabilities.

X
- Definition Other Financial Statement Details [Abstract] + References No definition available. + Details
Name: | intc_OtherFinancialStatementDetailsAbstract
Namespace Prefix: | intc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other Financial Statement Details [Text Block] + References No definition available. + Details
Name: | intc_OtherFinancialStatementDetailsTextBlock
Namespace Prefix: | intc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration